GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneTether Therapeutics Inc (XCNQ:GTTX) » Definitions » Capex-to-Operating-Income

GeneTether Therapeutics (XCNQ:GTTX) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is GeneTether Therapeutics Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

GeneTether Therapeutics's Capital Expenditure for the three months ended in Dec. 2023 was C$0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was C$-0.46 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


GeneTether Therapeutics Capex-to-Operating-Income Historical Data

The historical data trend for GeneTether Therapeutics's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneTether Therapeutics Capex-to-Operating-Income Chart

GeneTether Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
- - - -

GeneTether Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GeneTether Therapeutics's Capex-to-Operating-Income

For the Biotechnology subindustry, GeneTether Therapeutics's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GeneTether Therapeutics's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GeneTether Therapeutics's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where GeneTether Therapeutics's Capex-to-Operating-Income falls into.



GeneTether Therapeutics Capex-to-Operating-Income Calculation

GeneTether Therapeutics's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -1.002
=N/A

GeneTether Therapeutics's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -0.455
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GeneTether Therapeutics  (XCNQ:GTTX) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


GeneTether Therapeutics Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of GeneTether Therapeutics's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


GeneTether Therapeutics (XCNQ:GTTX) Business Description

Traded in Other Exchanges
N/A
Address
301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, V1Y 2B3
GeneTether Therapeutics Inc is a genetic medicines company focused on the development of high-efficiency precision gene editing for human therapeutics applications. It is engaged in creating gene-editing therapies based on the proprietary GeneTether platform. Further, it is focused on building a discovery pipeline for the treatment of rare, monogenic diseases of the kidney and the skin.

GeneTether Therapeutics (XCNQ:GTTX) Headlines

No Headlines